PubMed Health⌕ Search

Biomedical subjects

M T Goldfarb

Publications and source records attributed to M T Goldfarb.

28 records · Page 2Linked to original sources
PubMed1989

Topical tretinoin and photoaged skin.

Topical tretinoin has been proposed for the treatment of photoaged skin in recent years. In both open and double-blind trials, it has been successful in reversing some of the histologically and clinically apparent changes of photoaging. Many patients will experience a dermatitis due to retinoids during therapy, but are usually able to tolerate the treatment. Although clinical improvement may be modest, most patients are pleased with the result. We have found that optimal improvement is achieved by using tretinoin 0.1 percent cream to the limit of tolerance. By carefully instructing the patient on the application of the medication, the occurrence of initial dermatitis with therapy, and the type of improvement to expect, compliance with and tolerance of tretinoin therapy are greatly enhanced.

Administration, Topical↗
PubMed1988

Acitretin improves psoriasis in a dose-dependent fashion.

Acitretin, a metabolite of etretinate, was given to 38 patients for the treatment of psoriasis. During the first 8 weeks patients received either placebo, 10 mg, 25 mg, 50 mg, or 75 mg of acitretin daily in a double-blind manner. The dosages of 10 mg and 25 mg daily did not achieve any statistically significant improvement in psoriasis over placebo; however, both the 50 and 75 mg dosages were statistically significantly better than placebo. Side effects were primarily mucocutaneous and occurred in most patients receiving 25 mg or more of acitretin daily. After the double-blind period, patients continued treatment in an open fashion until they had received a total of 24 weeks of acitretin therapy. Most patients received 50 mg of acitretin daily, which adequately cleared their psoriasis. After approximately 3 months without acitretin, most patients required retreatment. Subsequent 24-week courses of therapy were generally effective and well tolerated. The most common laboratory abnormalities were elevations of triglyceride, cholesterol, and liver transaminase levels. The efficacy and side effects of acitretin appear to be similar to those of etretinate; the principal advantage of acitretin is its shorter half-life. Although acitretin is a potent teratogen, its rapid elimination makes it a viable treatment for psoriasis among women of childbearing potential.

Acitretin↗
PubMed1987

Etretinate therapy reduces inpatient treatment of psoriasis.

Twenty-six patients with a history of hospitalization for severe psoriasis were evaluated with regard to their use of inpatient therapy before and during therapy with etretinate. The duration of the pretherapy period and the etretinate treatment period averaged 5 and 4 years, respectively. Use of etretinate nearly eliminated inpatient therapy among these patients. Twelve of the patients stopped etretinate; their use of hospitalization for psoriasis remained below pre-etretinate levels in the two years after etretinate therapy was stopped. Etretinate therapy represents an effective and economical alternative to hospitalization for psoriasis treatment.

Ambulatory Care↗
PubMed1986

Effects of oral meclofenamate therapy in psoriasis.

One hundred three patients entered a study to evaluate the effects of oral meclofenamate sodium therapy on psoriasis. The first 4 weeks of the study were double-blind, with patients receiving either meclofenamate or placebo. Most patients receiving meclofenamate had no change in their psoriasis, in comparison with their pretherapy condition. There was no difference in the response of the psoriasis between the group taking meclofenamate and the group taking placebo. Eighty-nine patients continued in a 4-week open trial of meclofenamate. Approximately one third of the patients showed improvement, but this result appeared to be related to the open trial design. Since oral meclofenamate therapy was not associated with frequent worsening of psoriasis, it is an appropriate treatment for psoriatic arthritis.

Administration, Oral↗
PubMed1985

Keratoderma hereditaria mutilans (Vohwinkel's syndrome): a trial of isotretinoin.

An 8-year-old girl with the classic findings of keratoderma hereditaria mutilans (Vohwinkel's syndrome) was seen. Treatment with isotretinoin was instituted to decrease the hyperkeratosis and to prevent further autoamputation. After a 12-week course at 2 mg per kg per day, the patient had only minimal decrease in the amount of hyperkeratosis. Because of the well-known long-term risks of systematic retinoids and her suboptimal improvement, therapy was discontinued.

Child↗
PubMed1984

Nifedipine in scleroderma ulcerations.

Cutaneous ulcerations may be due to a variety of causes, including vasculitis, infections, arterial insufficiency, and microvascular damage. The net effect is diminished blood flow to the skin. Nifedipine, a calcium antagonist, has been shown to improve cutaneous blood flow and to alleviate reactive vasospastic ischemia (Raynaud's phenomenon). The authors report an ischemic ulcer of scleroderma showing visible improvement with nifedipine therapy.

Aged↗
PubMedDate not supplied

Cyclosporine A.

Explore the source record for details and available documents.

Administration, Oral↗